SKC podcast

#13 In search of justice - medical ethics for orphan drugs

Fri, 2023 / 06 / 30
Prof. Dr. Georg Marckmann holds the chair of ethics, history and theory of medicine at the Ludwig-Maximilians-University in Munich and is member of the board of the academy for ethics in medicine.

Ethical dilemma

In the Profcast "Rare diseases and their therapies" he talks with Prof. Dr. Matthias P. Schönermark about equitable access to healthcare for everyone, the dilemma of ethically appropriate evidence, the future of individualized therapies and new study formats, as well as the cost-benefit assessments of orphan drugs.

You can find Profcast #13 In search of justice - medical ethics for orphan drugs on Spotify und Apple Podcast (in German language only). Tune in!

About the Profcast

Our SKC podcast series "The Profcast - rare diseases and their therapies" aims to address the special circumstances of patients with rare diseases, the associated medicine and the challenges for research, development, economics and reimbursement. For this purpose, Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, speaks with patient representatives, payers, clinicians and scientists as well as industry representatives and also focuses on specific diseases. The word Profcast is a reference to professionals or professors, whom he welcomes as his guests.

The ambition behind this is to give an appropriate space to rare diseases and their treatment sine ira et studio. After all, the motto of the Rare Disease Day states it so aptly: "Rare is many". It is estimated that 4 million people in Germany and 300 million people worldwide are affected by a rare disease. In keeping with the Rare Disease Day, which traditionally takes place on the last day of February, the Profcast is published on the last day of a month.

About the author

Ihr Ansprechpartner Univ.-Prof. Dr. med. Matthias P. Schönermark
Univ.-Prof. Dr. med. Matthias P. Schönermark
Gründer und Geschäftsführer
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

Orphan Drugs


Orphan drugs and the specific market access challenges are at the core of our expertise.

Whitepaper


Successful market access for gene therapies - Strategic challenges and possible solutions
to the top